Dynamic changes and clinical significance of CXCR5,sPD-1 and Hcy in AIDS patients during therapy

doi:10.3969/j.issn.1673-8640.2022.02.001

Abstract

Abstract:

Objective To investigate the changes and clinical significance of serum C-X-C chemokine receptor 5（CXCR5）,soluble programmed cell death receptor-1（sPD-1） and homocysteine（Hcy） in acquired immune deficiency syndrome（AIDS） patients during antiretroviral therapy（ART）. Methods Totally,120 AIDS patients were enrolled in AIDS group,and 45 healthy subjects were enrolled as control group. The human immunodeficiency virus（HIV）-1 load,the absolute number of CD4⁺T cells,CXCR5,sPD-1,Hcy,blood lipids [triglyceride（TG）,total cholesterol（TC）,low-density lipoprotein cholesterol（LDL-C） and high-density lipoprotein cholesterol（HDL-C）] were determined in AIDS patients on 1 d before therapy and 3,6 and 12 months after therapy,respectively. Pearson correlation analysis was used to evaluate the correlations between each index and the absolute number of CD4⁺ T cells and HIV-1 load. Results Before therapy,the levels of sPD-1 and Hcy in AIDS group were higher than those in control group（P<0.01）,and CXCR5 and the absolute number of CD4⁺T cells were lower than those in control group（P<0.01）. Compared with those before therapy,with the prolongation of ART time,the absolute numbers of CD4⁺ T cells and CXCR5 levels in AIDS patients were increased（P<0.05）. The peak was reached at 6 months after therapy. Hcy,TC,TG and LDL-C were increased after 12 months of therapy（P<0.05）. HDL-C did not change. The HIV-1 load began to decrease after 3 months of therapy（P<0.05）,and the decrease was more significant after 6 months of therapy（P<0.05）. The level of serum sPD-1 decreased after 12 months of therapy（P<0.05）. Pearson correlation analysis showed that the absolute number of CD4⁺ T cells was positively correlated with CXCR5 and Hcy（r=0.192 and 0.401,P<0.05）,and there was a negative correlation with sPD-1（r=-0.708,P<0.05）. The HIV-1 load was negatively correlated with CXCR5 and Hcy（r=-0.682 and -0.318,P<0.05）,and it was positively correlated with sPD-1（r=0.368,P<0.05）. Conclusions The dynamic monitoring of the absolute number of CD4⁺ T cells,HIV-1 load,CXCR5,sPD-1,Hcy and blood lipid changes of AIDS patients during ART can help monitor the progress of HIV infection in time.

Key words: C-X-C chemokine receptor 5, Soluble programmed cell death receptor-1, Homocysteine, Acquired immune deficiency syndrome, Antiretroviral therapy

CLC Number:

R446.1

SHI Penghui, FAN Weiguang, ZHANG Zhen, SU Miaomiao, MENG Juan, LU Xinli. Dynamic changes and clinical significance of CXCR5,sPD-1 and Hcy in AIDS patients during therapy[J]. Laboratory Medicine, 2022, 37(2): 103-107.

Figures/Tables 2

References 29

[1]	ZHENG Y, ZHOU H, HE Y, et al. The immune pathogenesis of immune reconstitution inflammatory syndrome associated with highly active antiretroviral therapy in AIDS[J]. AIDS Res Hum Retroviruses, 2014, 30(12):1197-1202. DOI URL
[2]	尹科, 何盛华, 郭楠, 等. HIV/AIDS患者机会性感染与CD4+T淋巴细胞间的关联性[J]. 中国微生态学杂志, 2019, 31(2):167-170.
[3]	罗玲, 李太生. AIDS抗病毒治疗的历史、现状与未来[J]. 传染病信息, 2009, 22(6):321-324.
[4]	BANDERA A, COLELLA E, RIZZARDINI G, et al. Strategies to limit immune-activation in HIV patients[J]. Expert Rev Anti Infect Ther, 2017, 15(1):43-54. DOI URL
[5]	LEONG Y A, CHEN Y, ONG H S, et al. CXCR5⁺ follicular cytotoxic T cells control viral infection in B cell follicles[J]. Nat Immunol, 2016, 17(10):1187-1196. DOI URL
[6]	DEL ALCAZAR D, WANG Y, HE C, et al. Mapping the lineage relationship between CXCR⁺ and CXCR5^-CD4⁺T cells in HIV-infected human lymph nodes[J]. Cell Rep, 2019, 28(12):3047-3060. DOI URL
[7]	FROMENTIN R, DAFONSECA S, COSTINIUK C T, et al. PD-1 blockade potentiates HIV latency reversal ex vivo in CD4⁺T cells from ART-suppressed individuals[J]. Nat Commun, 2019, 10(1):814. DOI URL
[8]	HSUE P Y, WATERS D D. HIV infection and coronary heart disease:mechanisms and management[J]. Nat Rev Cardiol, 2019, 16(12):745-759. DOI URL
[9]	朱林, 章衍达, 陈明月, 等. 同型半胱氨酸与冠状动脉钙化的相关性[J]. 中华老年多器官疾病杂志, 2020, 19(2):93-97.
[10]	中华医学会感染病学分会艾滋病丙型肝炎学组, 中国疾病预防控制中心. 中国艾滋病诊疗指南(2018版)[J]. 新发传染病电子杂志, 2019, 4(2):65-84.
[11]	郑煜煌, 陈军, 雷建华, 等. 高效抗逆转录病毒疗法治疗HIV-1感染者的免疫学变化[J]. 中华皮肤科杂志, 2006, 39(5):281-284.
[12]	ZAUNDERS J, XU Y, KENT S J, et al. Divergent expression of CXCR5 and CCR5 on CD4+T cells and the paradoxical accumulation of T follicular helper cells during HIV infection[J]. Front Immunol, 2017, 8:495. DOI URL
[13]	MYLVAGANAM G H, RIOS D, ABDELAAL H M, et al. Dynamics of SIV-specific CXCR5+ CD8 T cells during chronic SIV infection[J]. Proc Natl Acad Sci U S A, 2017, 114(8):1976-1981. DOI URL
[14]	ADAMS P, ISERENTANT G, SERVAIS J Y, et al. Cytotoxic CD8+ T cells expressing CXCR5 are detectable in HIV-1 elite controllers after prolonged in vitro peptide stimulation[J]. Front Immun, 2021, 11:622343. DOI URL
[15]	HE R, HOU S, LIU C, et al. Follicular CXCR5- expressing CD8(+) T cells curtail chronic viral infection[J]. Nature, 2016, 537(7620):412-428. DOI URL
[16]	程林, 李迎飞, 陈伟梅, 等. HIV-1感染通过诱导IL-6促进可溶性PD-1的表达[J]. 中国艾滋病性病, 2019, 25(3):231-235.
[17]	CARTER L, FOUSER L A, JUSSIF J, et al. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2[J]. Eur J IMmunol, 2002, 32(3):634-643. DOI URL
[18]	肖金凤. 可溶性PD-1在HIV致病过程的作用及其分子机制的初步探讨[D]. 湛江:广东医科大学, 2017.
[19]	肖金凤, 徐六妹, 李莎茜, 等. HIV-1感染者血浆可溶性PD-1的含量及其临床意义[J]. 中国艾滋病性病, 2016, 22(11):853-855.
[20]	SEUNG E, DUDEK T E, ALLEN T M, et al. PD-1 blockade in chronically HIV-1 infected humanized mice suppressed viral loads[J]. PLoS One, 2013, 8(10):e77780. DOI URL
[21]	ZILBER E, MARTIN G E, WILLBERG C B, et al. Soluble plasma programmed death 1(PD-1) and Tim-3 in primary HIV infection[J]. AIDS, 2019, 33(7):1253-1256. DOI URL
[22]	陈琛, 赵长城, 王勇, 等. HIV/AIDS患者外周血程序性死亡受体-1的表达及临床意义[J]. 中国人兽共患病学报, 2019, 35(4):320-323.
[23]	UCCELLI M C, TORTI C, LAPADULA G, et al. Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAART[J]. Ann Nutr Metab, 2006, 50(3):247-252. DOI URL
[24]	CORIA-RAMIREZ E, CISNEROS L N, TREVIÑO-PEREZ S, et al. Effect of highly active antiretroviral therapy on homocysteine plasma concentrations in HIV-1-infect ed patients[J]. J Acquir Immune Defic Syndr, 2010, 54(5):477-481. DOI URL
[25]	GUARALDI G, VENTURA P, GARLASSI E, et al. Hyperhomocysteinaemia in HIV-infected patients:determinants of variability and correlations with predictors of cardiovascular disease[J]. HIV Med, 2009, 10(1):28-34.
[26]	李海莉. HIV感染者HAART中Hcy、LEP的变化及临床意义[D]. 桂林:桂林医学院, 2017.
[27]	CARR A, SAMARAS K, THORISDOTTIR A, et al. Diagnosis,prediction,and naturalcourse of HIV-1 protease-inhibitor-associated lipodystrophy,hyperlipidaemia,and diabetes mellitus:a cohort study[J]. Lancet, 1999, 353(9170):2093-2099. DOI URL
[28]	李晓琳. HIV感染者代谢标志物及其对感染者氧化应激及炎症反应作用的研究[D]. 沈阳:中国医科大学, 2020.
[29]	李俊敏. HIV感染与HAART治疗相关性脂代谢异常的临床特点及其机制研究[D]. 昆明:昆明医科大学, 2012.

组别	例数	CD4⁺T细胞/ （个/μL）	CXCR5/（μg/L）	sPD-1/ （ng/mL）	Hcy/ （μmol/L）	TC/ （mmol/L）	TG/ （mmol/L）	LDL-C/ （mmol/L）	HDL-C/ （mmol/L）
AIDS组	120	203±25	8.22±0.56	265.72±4.85	20.22±0.55	3.26±0.63	1.25±0.55	2.45±0.68	0.98±0.16
正常对照组	45	842±48	18.03±0.69	152.43±12.16	13.32±0.61	3.19±0.71	1.44±0.59	2.61±0.61	1.02±0.20
t值		20.45	19.14	14.99	14.55	0.12	1.78	0.29	1.33
P值		<0.01	<0.01	<0.01	<0.01	0.540	0.341	0.168	0.184

组别	例数	CD4⁺T细胞/ （个/μL）	CXCR5/（μg/L）	sPD-1/ （ng/mL）	Hcy/ （μmol/L）	TC/ （mmol/L）	TG/ （mmol/L）	LDL-C/ （mmol/L）	HDL-C/ （mmol/L）
AIDS组	120	203±25	8.22±0.56	265.72±4.85	20.22±0.55	3.26±0.63	1.25±0.55	2.45±0.68	0.98±0.16
正常对照组	45	842±48	18.03±0.69	152.43±12.16	13.32±0.61	3.19±0.71	1.44±0.59	2.61±0.61	1.02±0.20
t值		20.45	19.14	14.99	14.55	0.12	1.78	0.29	1.33
P值		<0.01	<0.01	<0.01	<0.01	0.540	0.341	0.168	0.184

项目	CD4⁺T细胞/（个/μL）	HIV-1/（lg拷贝/mL）	CXCR5/（μg/L）		sPD-1/（ng/mL）
治疗前	203±25	5.13±0.36	8.22±0.56		265.72±4.85
治疗3个月	346±32^*	4.12±0.22^*	12.02±0.48^*		268.32±5.02
治疗6个月	518±29^*#	1.92±0.24^*#	17.22±0.51^*#		271.04±4.69
治疗12个月	510±43^*#	1.80±0.39^*#△	17.03±0.44^*#		184.65±5.44^*#
F值	62.34	84.21	225.75		78.14
P值	<0.01	<0.01	<0.01		<0.01
项目	Hcy/（μmol/L）	TC/（mmol/L）	TG/（mmol/L）	LDL-C/（mmol/L）	HDL-C/（mmol/L）
治疗前	20.22±0.55	3.26±0.63	1.25±0.55	2.45±0.68	0.98±0.16
治疗3个月	21.02±0.69^*	3.75±0.78^*	1.98±0.36^*	3.11±0.28^*	1.01±0.23^*
治疗6个月	22.43±0.74^*#	4.72±0.61^*#	3.45±0.42^*#	4.21±0.41^*#	0.91±0.19^*#
治疗12个月	31.55±0.86^*#△	5.98±0.44^*#△	4.63±0.52^*#△	5.02±0.63^*#△	0.90±0.33^*#△
F值	36.41	10.99	31.14	14.45	0.13
P值	<0.01	<0.01	<0.01	<0.01	0.94

项目	CD4⁺T细胞/（个/μL）	HIV-1/（lg拷贝/mL）	CXCR5/（μg/L）		sPD-1/（ng/mL）
治疗前	203±25	5.13±0.36	8.22±0.56		265.72±4.85
治疗3个月	346±32^*	4.12±0.22^*	12.02±0.48^*		268.32±5.02
治疗6个月	518±29^*#	1.92±0.24^*#	17.22±0.51^*#		271.04±4.69
治疗12个月	510±43^*#	1.80±0.39^*#△	17.03±0.44^*#		184.65±5.44^*#
F值	62.34	84.21	225.75		78.14
P值	<0.01	<0.01	<0.01		<0.01
项目	Hcy/（μmol/L）	TC/（mmol/L）	TG/（mmol/L）	LDL-C/（mmol/L）	HDL-C/（mmol/L）
治疗前	20.22±0.55	3.26±0.63	1.25±0.55	2.45±0.68	0.98±0.16
治疗3个月	21.02±0.69^*	3.75±0.78^*	1.98±0.36^*	3.11±0.28^*	1.01±0.23^*
治疗6个月	22.43±0.74^*#	4.72±0.61^*#	3.45±0.42^*#	4.21±0.41^*#	0.91±0.19^*#
治疗12个月	31.55±0.86^*#△	5.98±0.44^*#△	4.63±0.52^*#△	5.02±0.63^*#△	0.90±0.33^*#△
F值	36.41	10.99	31.14	14.45	0.13
P值	<0.01	<0.01	<0.01	<0.01	0.94